A blood test that can detect tumors may help physicians to personalize cancer treatments, and offer a way out if cancer has returned or has spread in this way could also determine the effectiveness of treatments.

Although there will be years until this technology is available in hospitals, a study has shown for the first time this type of blood test may be in the near future a reality.

At present, tests such as magnetic resonance images are most commonly used to see if a tumor persists or expanded after surgery to remove it. Despite its accuracy, can be late for the detection and treatment of cancer. This new procedure would detect the persistence of the disease only days or weeks after the surgery performed

This study, to be published in the journal Science Translational Medicine dated Feb. 24, was presented Thursday at the annual conference of the American Association for the Advancement of Science (AAAS), held between 18 and 22 February in San Diego (southern California).

Although by now the genome sequencing of tumors is worth about € 3,700 per patient, researchers say the trend is that the price will decline to become even more cost effective than current scanners.